Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | OGFRL1 | Q5TC84 | 10/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11901295 | 1.00 | TP53 (0.48) | TP53OGFRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL11901538 | 0.89 | OPRM1 (0.47) | TP53OGFRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL11901014 | 0.77 | TP53 (0.62) | TP53OGFRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL11900687 | 0.77 | TP53 (0.62) | TP53OGFRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL11901013 | 0.77 | TP53 (0.62) | TP53OGFRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL11901298 | 0.76 | PIK3CD (0.46) | TP53OGFRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL11964466 | 0.76 | PIK3CD (0.45) | TP53OGFRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL17718406 | 0.75 | POLB (0.47) | ALDH1A1HTTKMT2A | |
| SCHEMBL2503479 | 0.74 | SMN1; SMN2 (0.42) | OGFRL1OPRM1OPRD1ALDH1A1HTT | |
| SCHEMBL2507650 | 0.74 | PIK3CD (0.49) | PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | TP53 620/4885OGFRL1 3508/4885OPRM1 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.